GeoVax Labs, Inc. (GOVX)

Market Cap	3.46M
Revenue (ttm)	n/a
Net Income (ttm)	-25.97M
Shares Out	2.31M
EPS (ttm)	-14.29
PE Ratio	n/a
Forward PE	10.63
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,281
Open	1.635
Previous Close	1.540
Day's Range	1.500 - 1.635
52-Week Range	1.450 - 11.535
Beta	2.92
Analysts	Strong Buy
Price Target	105.00 (+6,900.0%)
Earnings Date	May 2, 2024

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM0...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: GOVX

Analyst Forecast

According to 2 analysts, the average rating for GOVX stock is "Strong Buy." The 12-month stock price forecast is $105.0, which is an increase of 6,900.00% from the latest price.

Price Target

$105.0

(6,900.00% upside)

Analyst Consensus: Strong Buy